J2 inhibits immune function of CD4+ and CD8+ T cells in allogeneic penetrating keratoplasty rat models

doi:10.3969/j.issn.2095-4344.2016.05.020

Chinese Journal of Tissue Engineering Research ›› 2016, Vol. 20 ›› Issue (5): 723-728.doi: 10.3969/j.issn.2095-4344.2016.05.020

Previous Articles Next Articles

J2 inhibits immune function of CD4+ and CD8+ T cells in allogeneic penetrating keratoplasty rat models

Guo Hui-ling^{1, 2}, Du Gai-ping^{2, 3}, Wang Li-qiang², Gong Yu-bo¹, Yan Hong-xin¹, Huang Yi-fei²

¹Department of Ophthalmology, the 306 Hospital of Chinese PLA, Beijing 100101, China; ²Department of Ophthalmology, General Hospital of Chinese PLA, Beijing 100853, China; ³Department of Ophthalmology, the 401 Hospital of Chinese PLA, Qingdao 266000, Shandong Province, China

Received:2015-11-28 Online:2016-01-29 Published:2016-01-29
Contact: Huang Yi-fei, M.D., Chief physician, Department of Ophthalmology, General Hospital of Chinese PLA, Beijing 100853, China
About author:Guo Hui-ling, M.D., Attending physician, Department of Ophthalmology, the 306 Hospital of Chinese PLA, Beijing 100101, China; Department of Ophthalmology, General Hospital of Chinese PLA, Beijing 100853, China
Supported by:
the National Natural Science Foundation of China, No. 30973245; the National Postdoctoral Science Foundation, No. 20100481481

Abstract

Abstract:

BACKGROUND: J2 takes functional domain (MHC CD4-D1/) of complex conjugate of CD4 molecule and MHC class II molecule as a target, and is a small molecule compound obtained by computer screening from a chemical data containing hundreds of thousands of organic compounds. In the previous study, J2 was used in mouse models of skin transplantation and keratoplasty by oral and intraperitoneal injection. Results verified that J2 could prolong the survival time of grafts, and suppress occurrence of rejection. To better play the role of a drug targeting and to reduce systemic toxicity, J2 will be further utilized in local treatment of keratoplasty rejection.
OBJECTIVE: To investigate the inhibitory effect of new immunosuppressive agent J2 on CD4+ and CD8+ T cell immune functions in rat models receiving allogenic penetrating keratoplasty.
METHODS: Allogeneic penetrating keratoplasty model was established using the adult female Wistar rats as donors and Sprague-Dawley rats as recipients. Group A: normal Sprague-Dawley rats were injected with 0.05 mL placebo subconjunctivally. Surgery rats were randomly divided into three groups. Group B: allograft rats were injected with 0.05 mL placebo subconjunctivally after autologous keratoplasty. Group C: allograft rats were injected with 0.05 mL placebo subconjunctivally. Group D: allograft rats were injected with 1% J2-nanosuspension 0.05 mL subconjunctivally. The distribution of T cell subsets in peripheral blood was detected using flow cytometry at 3 days, 1, 2 and 3 weeks after transplantation and compared among groups.
RESULTS AND CONCLUSION: There was no significant difference in total CD3+ T cells, CD4+ T cells, CD8+ T cells and CD4+/CD8+ in peripheral blood lymphocytes in group B at various time points. At 3 days and 1 week after surgery in group C, no significant difference in total CD3+ T cells, CD4+ T cells and CD8+ T cells was detected. At 1 and 2 weeks, the number of total CD3+ T cells, CD4+ T cells and CD8+ T cells increased, showing significant differences (P < 0.05). In group D, no significant hyperplasy was found in CD4+ T cells and CD8+ T cells at 1 and 2 weeks. The horizontal comparison of the same time point: the total CD3+ T lymphocytes of group D was significantly less than group C at 3 days, 1 and 2 weeks after operation (P < 0.05), whereas there was no significant difference at 3 weeks between the group D and group C. The number of CD4+ T lymphocytes in group D was less than in group C at 3 days and 1 week, but with no significant difference. The ratio of CD4+/CD8+ had no significant difference in group D compared with group C at 3 days, 1 and 3 weeks. J2 inhibits T lymphocyte proliferation and then inhibits T cell-mediated corneal allograft rejection.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Guo Hui-ling, Du Gai-ping, Wang Li-qiang, Gong Yu-bo,Yan Hong-xin, Huang Yi-fei. J2 inhibits immune function of CD4+ and CD8+ T cells in allogeneic penetrating keratoplasty rat models[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(5): 723-728.

Figures/Tables 3

References

[1] Tsai RJF, Tseng SCG. Human allograft limbal transplantation of corneal surface reconstructions. Cornea. 1994;13: 389.

[2] Cameron AM, Steinet JP, Sabatini DM, et al. Immunophilin FK506 binding protein associated with inositol 1, 4, 5 triSphosphaterecept or modulates calcium flux. Proc Nat Acad Sci. 1995;92(5):1784-1788.

[3] Boisgerault F, Liu Y, Anosova N, et al. Role of CD4+ and CD8+ T cells in allorecognition: lessons from cornealtransplantation. J Immunol. 2001;167(4): 1891-1899.

[4] 徐筱杰,主编.计算机辅助药物分子设计[M].北京:化学工业出版社,2004:12.

[5] 宋云龙,陆倍倍,张万年.基于结构的计算机辅助药物设计方法学与应用研究[J].药学进展, 2002, 26(6) :359-364.

[6] 何新华,谢云德,肖鹤,等.新型CD4抑制剂J2的合成及其活性评价[J]. 中国药物化学杂志, 2009, 19(4):290-292.

[7] 张磊,冯健男,崔健,等.J2小分子化合物能有效抑制小鼠急性移植物抗宿主反应的实验研究[J].军事医学科学院院刊, 2008, 32(6): 519-522.

[8] He X, Jian NF, Xin HH, et al. Potent inhibition of the CD4- dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1. Mol Immunol. 2007;44: 784-795.

[9] He X, Han Z, Zu YY, et al. J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo. Trans Immunol.2007;18:130-137.

[10] Da JW, Han Z, Guo JC, et al. Further study on molecular biological effects of CD4 D1 inhibitor J2 on allografts following corneal transplantation in mice. Sci Res Ess. 2010; 5(1): 63-70.

[11] 王大江,黄一飞,张晗,等.小分子化合物J2抑制小鼠角膜移植术后排斥反应的研究[J].中华眼科杂志,2009, 45(4):350-355.

[12] 王大江,黄一飞,张晗,等.小分子化合物J2对小鼠角膜移植术后植片RANTES基因表达的影响[J]. 眼视光学杂志, 2008,10(3): 174-177.

[13] 张晗,黄一飞,王丽强.小分子免疫抑制剂J2抗移植排斥的实验研究[J]. 解放军药学学报, 2006, 22(2):115-118.

[14] 张晗,黄一飞,王丽强.基于CD4分子构型设计的小分子免疫抑制药J2抗移植排斥反应的作用研究[J]. 医药导报, 2006, 25(8): 723-725.

[15] 张晗,黄一飞,王丽强.小分子化合物J2在抑制小鼠角膜移植排斥反应中作用的初步研究[J]. 中华眼科杂志,2007, 43(7):608- 612.

[16] 王大江,黄一飞,张晗.小分子化合物J2对小鼠淋巴细胞的影响[J]. 解放军药学学报,2007, 23(2): 81-84.

[17] 赵勇,主编.移植免疫耐受[M]. 北京:中国医药科技出版社, 2005: 2-11.

[18] 杨朝忠,耿燕,姚晓明,主编. 眼表移植学[M]. 北京:军事医学科学出版社,2008:138-141.

[19] Larkin DF, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol. 1997;107: 381-391

[20] Kiritoshi A, SundarRaj N, Thoft RA. Differentiation in cultured limbal epithelium as defined by keratin expression. Invest Opthalmol Vis Sic. 1991;32: 3073-3077.

[21] Kenyon KR, Tseng SCG. Limal autograft transplantation for ocular surface disorders. Ophthalmology. 1989;96: 709.

[22] Sarikcioglu L, Duygulu E, Aydin H, et al. Effects of intrathecal administration of FK506 after sciatic nerve crush injury. J Reconstr Microsurg. 2006;22(8):649-654.

[23] Hontanilla B, Yeste L, Auba C, et al. Neurnonal quantification in cold preserved nerve autografts and treatment with FK506 through osmotic pump s compared to nerve autografts. J Reconstr Microsurg. 2006;22(5):363-374.

[24] 陈实,主编.移植免疫学[M]. 武汉:湖北科学技术出版社,1998: 78-91.

[25] Streilein JW, Arancibia-Caracamo C, Osawa H. The role o f minor histocompatibility alloantigens in penetrating keratoplasty. Dev Ophthalmol. 2003;36: 74-88.

[26] Boisgérault F, Liu Y, Anosova N, et al. Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation. J Immunol. 2001;167(4): 1891-1899.

[27] Pleyer U, Milani JK, Dukes A, et al. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci. 1995; 36(1): 52-61.

[28] Pindjáková J, Vítová A, Krulová M, et al. Corneal rat-to-mouse xenotransplantation and the effects of anti-CD4 or anti-CD8 treatment on cytokine and nitric oxide production Transpl Int. 2005;18(7):854-862.

[29] Yamada J, Kurimoto I, Streilein W. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci. 1999; 40: 2614-2621

[30] 史伟云,谢立信. CD4和CD8基因敲除鼠行穿透性角膜移植术后免疫排斥特征的研究[J].中华眼科杂志,2005, 41(4): 350-354.

[31] 刘彤,王鹏志,朱理玮,等.大鼠小肠移植后外周血T淋巴细胞亚群的变化[J]. 中华器官移植杂志,1996, 17(1):15-17.

[32] 吴京,王小宁.角膜移植排斥反应的实验研究Ⅱ-T淋巴细胞亚群及T-CEC的变化[J]. 眼科新进展,1997, 17(3):137-139.

[33] Creemers P, Brink J, Wainwright H, et al. Evaluation of peripheral blood CD4 and CD8 lymphocyte subsets, CD69 expression and histologic rejection grade as diagnostic markers for the presence of cardiac allograft rejection. TransplImmunol. 2002;10(4): 285-292.

[34] Völker-Dieben HJ, Claas FH, Schreuder GM, et al. Beneficial effect of HLA-DR matching on the survival of corneal allografts. Transplantation.2000; 70: 640-648.

[35] Sheldon S, Poulton K. HLA typing and its influence on organ transplantation. Methods Mol Biol. 2006;333: 157-174.

[36] Reinhard T, Böhringer D, Enczmann J, et al. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye (Lond). 2004;18(3): 269-277.

J2 inhibits immune function of CD4+ and CD8+ T cells in allogeneic penetrating keratoplasty rat models

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References

Related Articles 0

Recommended Articles

Metrics

Comments